Johnson Matthey (OTCMKTS:JMPLY) Downgraded by Barclays
Several other equities analysts have also weighed in on the company. ValuEngine lowered Johnson Matthey from a hold rating to a sell rating in a research note on Thursday, July 18th. Zacks Investment Research lowered Johnson Matthey from a hold rating to a strong sell rating in a research note on Friday, July 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $94.00.
OTCMKTS JMPLY opened at $80.31 on Tuesday. The firm has a market capitalization of $7.75 billion, a P/E ratio of 13.47, a P/E/G ratio of 1.83 and a beta of 1.52. Johnson Matthey has a 1-year low of $66.88 and a 1-year high of $95.48. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.64 and a quick ratio of 1.00. The business’s 50-day simple moving average is $73.02 and its 200-day simple moving average is $80.89.
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Featured Article: How does a margin account work?
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.